Genmab A/S (OTCMKTS:GNMSF) Shares Gap Down – Should You Sell?

Genmab A/S (OTCMKTS:GNMSF)’s stock price gapped down before the market opened on Thursday . The stock had previously closed at $352.00, but opened at $336.25. Genmab A/S shares last traded at $336.25, with a volume of 1 shares.

Genmab A/S Stock Performance

The company’s fifty day moving average price is $317.53 and its 200 day moving average price is $279.70. The firm has a market capitalization of $22.11 billion, a price-to-earnings ratio of 14.33 and a beta of 0.87.

Genmab A/S (OTCMKTS:GNMSF) last issued its earnings results on Thursday, November 6th. The company reported $6.46 EPS for the quarter, beating analysts’ consensus estimates of $4.86 by $1.60. The company had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1 billion. Genmab A/S had a return on equity of 23.98% and a net margin of 41.36%.

Genmab A/S Company Profile

Genmab A/S is a biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer and other serious diseases. The company’s core expertise lies in its proprietary antibody platforms, including DuoBody®, HexaBody® and HexElect®, which enable the design and engineering of novel bispecific and enhanced-effector antibodies. Genmab’s science-driven approach integrates advanced protein engineering with insights into tumor biology to generate candidates that can engage the immune system, disrupt disease pathways and offer potential safety and efficacy advantages over conventional therapies.

Founded in 1999 and headquartered in Copenhagen, Denmark, Genmab has grown into a global organization with research and development facilities in Utrecht, the Netherlands, and commercial and clinical support offices in the United States.